Antimuscarinics dominate the global overactive bladder therapeutics market due to their wide availability and relatively low cost. However, they are associated with side effects such as dry mouth, constipation, and blurred vision, which can limit their use. Beta-3 agonists, on the other hand, have fewer side effects and are generally better tolerated, but they are more expensive than antimuscarinics. In addition to drug therapy, behavioral therapies such as bladder training, pelvic floor muscle exercises, and biofeedback are also used to manage OAB. These therapies aim to improve bladder control and reduce urinary frequency and urgency. Lifestyle modifications such as weight loss, reducing fluid intake before bedtime, and avoiding bladder irritants such as caffeine and alcohol can also help manage OAB symptoms.
The anticholinergics segment is expected to maintain its dominance in the market, accounting for the largest share of the Overactive Bladder Therapeutics Market in 2025. However, the mirabegron segment is expected to grow at a faster rate, due to the increasing popularity of this drug and its effectiveness in treating OAB. Geographically, North America is expected to dominate the overactive bladder therapeutics market, due to the high prevalence of OAB in this region and the availability of advanced healthcare infrastructure.
Read more @ https://influentialblogging.blogspot.com/2023/04/global-overactive-bladder-therapeutics.html
